BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
At least 55 injured in Russia after train crashes, overturns - 2US EPA will reassess safety of herbicide paraquat, says its chief
- 3Vote In favor of Your Favored Language Learning Applications
- 4Discovery off Israel’s coast reveals earliest known 2,600-year-old shipment of raw iron
- 5Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- The Best Internet based Courses for Expertise Improvement
- Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- German men need approval for stays abroad under military service law
- 4 African Vacationer Locations
- How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- Computerized Strengthening d: A Survey of \Upgrading Efficiency\ Programming Application
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
